Paratek Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Paratek Pharmaceuticals

05/05/2022 13:00

* Paratek Pharmaceuticals Inc  PRTK.OQ  reported a quarterly
adjusted loss of 35 cents​​ per share for the quarter ended in
March. The mean expectation of three analysts for the quarter
was for a loss of 35 cents per share.
    * Revenue fell 95.9% to $672.00 thousand from a year ago; 
analysts expected $27.15 million. 
    * Paratek Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 35 cents​.
    * The mean earnings estimate of analysts had fallen by
about 27.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Paratek Pharmaceuticals Inc shares had fallen by 26.6%
this
quarter and lost 51.4% so far this year.
    * The company reported a quarterly loss of $17.91 million.
    * Wall Street's median 12-month price target for Paratek
Pharmaceuticals Inc is $17.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 5 at 12:00 p.m.  ​All
figures in US dollars unless otherwise stated